LivaNova PLC (LIVN) News
Follow LivaNova PLC (LIVN) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 8 public stories across 6 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
LivaNova to Announce Third-Quarter 2026 Results
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its third-quarter 2026 results on Wed., Nov. 4, 2026, at 1 p.m. Greenwich Mean Time (8 a.m. Eastern Standar
NEWS | Sep 23, 2026, 01:01 PM UTC
L
LIVN: Growth momentum continues with innovation, reimbursement, and product upgrades fueling future gains
Sustained growth is driven by talent, execution, and innovation, with strong tailwinds from reimbursement and clinical data in epilepsy and supply chain improvements. Margin expansion will be reinvested in new growth are
NEWS | Sep 15, 2026, 04:53 PM UTC
L
LIVN: Growth is fueled by innovation, new product launches, and strong clinical and reimbursement tailwinds
Sustained double-digit growth is driven by talent, execution, and innovation, with new market entries and product launches in epilepsy and cardiopulmonary segments. Margin expansion will fund OSA investments, and strong
NEWS | Sep 15, 2026, 04:27 PM UTC
L
Piper Sandler raises LivaNova price target to $90 from $87
Piper Sandler raised its LivaNova price target to $90.00 per share from $87.00, according to a Benzinga ratings-action item.
EQUITY | Sep 02, 2026, 04:42 PM UTC
L
LivaNova Raises FY2026 Adj EPS Guidance from $4.20-$4.30 to $4.30-$4.40 vs $4.25 Est; Raises FY2026 Sales Guidance from $1.445B-$1.458B to $
LivaNova (NASDAQ: LIVN ) raises FY2026 Adj EPS guidance from $4.20-$4.30 to $4.30-$4.40 vs $4.25 analyst estimate. Raises FY2026 sales outlook from $1.445 billion-$1.458 billion to $1.499 billion-$1.513 billion vs $1.507
EARNINGS | Aug 05, 2026, 10:01 AM UTC
L
This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Baird analyst Dav
EQUITY | Jul 01, 2026, 11:02 AM UTC
L
Freedom Capital Markets Initiates Coverage On LivaNova with Hold Rating, Announces Price Target of $81
Freedom Capital Markets analyst Keith Hinton initiates coverage on LivaNova (NASDAQ: LIVN ) with a Hold rating and announces Price Target of $81.
EQUITY | Jul 01, 2026, 08:43 AM UTC
M
LIVN: Keybanc Raises Target
Keybanc maintains overweight rating on LivaNova and raises price target to $92
EQUITY | Jun 22, 2026, 01:15 PM UTC